We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00976755
Recruitment Status : Active, not recruiting
First Posted : September 14, 2009
Last Update Posted : May 5, 2017
Sponsor:
Information provided by (Responsible Party):

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Primary Completion Date : November 29, 2012
  Estimated Study Completion Date : December 31, 2017
Publications:
Templeton A, Rothermundt C, Cathomas R, et al.: Everolimus as first-line therapy in nonrapidly progressive metastatic castration-resistant prostate cancer (mCRPC): A multicenter phase II trial (SAKK 08/08). [Abstract] J Clin Oncol 29 (Suppl 15): A-4588, 2011.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):